Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis.

Robert F KushnerAnders Fink-JensenOfir FrenkelBarbara M McGowanBryan GoldmanMaria OvervadThomas A Wadden

Published in: Obesity (Silver Spring, Md.) (2023)

In adults with overweight/obesity, semaglutide provided clinically meaningful weight loss regardless of baseline AD use, with an AE profile consistent with previous studies.

Keyphrases

weight loss
bariatric surgery
roux en y gastric bypass
gastric bypass
weight gain
major depressive disorder
insulin resistance
metabolic syndrome
glycemic control
type diabetes
clinical trial
body mass index
randomized controlled trial
high fat diet induced
open label